Beneficial effects of cholesterol absorption inhibitor,ezetimibe on impaired endothelial function in patients with metabolic syndrome.
Not Applicable
- Conditions
- Metabolic syndrome
- Registration Number
- JPRN-UMIN000001305
- Lead Sponsor
- Tohoku University Graduate School of Medicine EZET-trial group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1) History of drug hypersensitivity to ezetimibe. 2) History of chronic heart failure. 3) Patients who have insulin therapy. 4) Patients who have severe liver dysfunction. Patients who have severe kidney dysfunction. 5) Patients who have secondary dyslipidemia or drug-induced dyslipidemia. 6) Pregnant or possibly pregnant patients. 7) Other patients deemed unsuitable as subjects of the study by the treating physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method